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Reporting Summary
Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency 
in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.
Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main 
text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one- or two-sided 
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested
A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND 
variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Give P values as exact values whenever suitable.
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
Clearly defined error bars 
State explicitly what error bars represent (e.g. SD, SE, CI)
Our web collection on statistics for biologists may be useful.
Software and code
Policy information about availability of computer code
Data collection No software was used to collect data.
Data analysis The following software/code was used to analyze data: 
FlowJo v10 for analyzing flow cytometry data. 
GraphPad Prism v6  for statistical analyses. 
Custom code for analyzing sequencing data was used. The code is deposited in GitHub (https://github.com/Baltimore-Lab/nat-methods-
SABR-trogo). 
Sequence Alignment was done using Burrows-Wheeler Alignment: 
Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-1760, doi:10.1093/ 
bioinformatics/btp324 (2009).
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers 
upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
2nature research  |  reporting sum
m
ary
April 2018
Data
Policy information about availability of data
All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: 
- Accession codes, unique identifiers, or web links for publicly available datasets 
- A list of figures that have associated raw data 
- A description of any restrictions on data availability
The data that support the findings of this study are available from the corresponding author upon request.The list of epitopes in the antigen libraries can be found 
in supplementary tables 1 and 2. 
Field-specific reporting
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Life sciences Behavioural & social sciences  Ecological, evolutionary & environmental sciences
For a reference copy of the document with all sections, see nature.com/authors/policies/ReportingSummary-flat.pdf
Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size We used minimal sample size for statistical comparisons.
Data exclusions No data exclusions
Replication  All attempt at replication were successful.
Randomization Randomization is not relevant to this study because no comparisons between experimental groups were made.
Blinding Blinding was not possible because the target epitopes for each TCR tested are known.
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Materials & experimental systems
n/a Involved in the study
Unique biological materials
Antibodies
Eukaryotic cell lines
Palaeontology
Animals and other organisms
Human research participants
Methods
n/a Involved in the study
ChIP-seq
Flow cytometry
MRI-based neuroimaging
Unique biological materials
Policy information about availability of materials
Obtaining unique materials The antigen libraries are available from the corresponding author upon request.
Antibodies
Antibodies used PE anti-human CD3 Antibody (BioLegend, 317308, Clone OKT3, lot .B225591). Used at 1:200. 
Brilliant Violet 510™ anti-human CD8 Antibody (BioLegend, 344731, Clone SK1, lot. B236260). Used at 1:200. 
Pacific Blue™ anti-human TCR α/β Antibody (BioLegend, 306715, Clone IP26, lot. B210800). Used at 1:100. 
PE/Cy7 anti-human TCR α/β Antibody (BioLegend, 306720, Clone IP26, lot. B247926). Used at 1:100. 
PE/Cy7 anti-mouse TCR β chain Antibody (BioLegend, 109222, Clone H57-597, lot. B241527). Used at 1:200. 
PE anti-human CD271 (NGFR) Antibody (BioLegend, 345106, Clone ME20.4, lot. B215084). Used at 1:1000. 
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APC anti-human CD271 (NGFR) Antibody (BioLegend, 345108, Clone ME20.4, lot. B236644). Used at 1:1000. 
Brilliant Violet 510™ anti-human HLA-A2 Antibody (BioLegend, 343319, Clone BB7.2, lot. B212450). Used at 1:200. 
Pacific Blue™ anti-human HLA-A2 Antibody (BioLegend, 343312, Clone BB7.2, lot. B231554). Used at 1:200. 
 
 
Validation Antibodies were validated by the company; refer to the company website for detailed validation analysis.
Eukaryotic cell lines
Policy information about cell lines
Cell line source(s) Jurkat Cells, Clone E6-1 purchased from ATCC, Manassas, VA; Cat # TIB¬-152 
K562 Cells purchased from ATCC, Manassas, VA; Cat # CCL-243 
Primary T Cells purchased from UCLA, CFAR Virology Core  
HEK-293T Cells purchased from ATCC, Manassas, VA Cat # CRL-3216 
Authentication None of the cell lines were authenticated
Mycoplasma contamination Cell lines were not tested for mycoplasma
Commonly misidentified lines
(See ICLAC register)
No commonly misidentified cell lines used
Flow Cytometry
Plots
Confirm that:
The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
Methodology
Sample preparation Jurkat and K562 cells
Instrument MACSQuant® Analyzer 10
Software TreeStar FlowJo® Flow Cytometric Data Analysis Software v10.1
Cell population abundance Jurkat and K562 cells in a 5:1 or 2:1 ratio
Gating strategy detailed in the supplementary information
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
